Applied Clinical Trials Direct
Having trouble viewing this e-mail? Click here.
  October 31, 2013


In This Edition
News Roundup: AstraZeneca Initiates Phase III Trial for NSCLC
Articles: Streamline and Improve Study Start-Up
Blog Posts: Finding Ways to Finance the Growing Costs of Clinical Trials
Marketplace: Marketplace

News Roundup
bullet Phase III Trial for Heart Failure Authorized to Enroll
bullet AstraZeneca Initiates Phase III Trial for NSCLC
bullet US Oncology Research Collaborates wit BioMarin on Phase III Study
bullet Lilly’s RAINBOW Trial Meets Primary Endpoint in Phase III Cancer Trial

Articles
bullet Ethnobridging to Accelerate Drug Development
bullet Streamline and Improve Study Start-Up

Sponsored
Applied Clinical Trials launches new e-book, Risk-Based Monitoring for Clinical Trials
Download here.

Blogs Posts
bullet Finding Ways to Finance the Growing Costs of Clinical Trials
bullet What New Proof of Concept Might Mean for the Future

Sponsored
Implementing a new approach to study design: what can I expect?
On Demand Webcast
Register Free at: www.appliedclinicaltrialsonline.com/studydesign

Events
bullet Sponsor and CRO Business Process Integration

Sponsored
Applying Pharmacogenomics to enable real time decisions during drug development
On Demand Webcast
Click here to Register Free.

Marketplace

Sponsored
Medidata
IRT and EDC: The Unified Experience describes how sponsors and CROs can integrate and streamline complex processes spanning randomization, trial supply management and data collection for better clinical trials. Read more.

Sponsored
Drug Development Strategies in China
Pharma and biotech firms who are relative newcomers to the Chinese market aren't aware that the regulatory climate has changed dramatically in recent years. SFDA approval times for Clinical Trials Approvals have dropped to 7-9 months for small molecules. There are also opportunities in China for sponsors that have not yet completed Phase II trials to create a parallel approval strategy. Even without final details (like final dosing) it’s possible to file a CTA for Phase III based on the most current early phase results. This parallel submission strategy can shave several months off the final approval time in China. Read more.

Sponsored
Implementing Rare Disease Registries: Unique Challenges & Proactive Solutions
On Demand Webcast
To Register Free Click here.


Sponsored
Risk-based Monitoring Tools for Application
Live Webcast: Wednesday, November 6, 2013 at 11:00am EST
To Register Free Click here.



CHINA REPORT
China is the third largest pharmaceutical market in the world and will become the second largest ahead of Japan by 2015. Everything you need to know to do business in the country; key economic sector data and exclusive interviews from regional leaders. Read More.

Follow Us

Ask The Editor

Lisa Henderson
Editor in Chief
[email protected]

 

CRO/Sponsor

Risk-Based Monitoring Conference SPOTLIGHT EVENT
Sponsor/CRO Systems & Business Process Integration
Nov. 13-14, 2013
Raleigh, NC

Download Brochure
Register

More in CRO/Sponsor